Quoin Pharma's QRX003 receives orphan drug designation in Japan

Japan's MHLW granted orphan drug designation for QRX003 in Netherton Syndrome, providing up to 10 years of market exclusivity and regulatory incentives. This adds to prior FDA and EMA designations, supporting Quoin's strategy to self-commercialize in Japan as a core market.